Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
复制标题
Survivin 是预后不良的乳腺癌患者短期生存的独立预测因子。
DOI：
10.1038/sj.bjc.6603616
复制
发表时间：
2007-02-26
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
既定的临床病理因素可以将乳腺癌患者分为预后良好和预后不良两类，但即使在这些群体中，行为和对治疗的反应也可能不同。这项研究检验了细胞周期和凋亡调节蛋白在预测预后不良组的行为方面的价值。应用免疫组织化学方法检测165例乳腺癌患者的增殖、细胞凋亡、P53、磷酸化P53、p21、Chk2、bcl2、bax、Survivin和XIAP的表达。所有患者都接受了化疗和/或激素治疗，主要是T2期，结节阳性，III级，只有一半雌激素受体(ER)阳性。高增殖、磷酸化的p53、Chk2和Survivin的表达与III级和ER缺乏有关，而低增殖、p21和bcl2的表达与ER的较高分级和阳性有关。单因素分析显示，分化程度、细胞增殖、磷酸化P53、bcl2、ER和Survivin与生存期有关。在多因素分析中，分级(P=0.001)和Survivin(P=0.005)是独立的预后因素，III级和Survivin的存在与较短的生存期有关。后者尤其适用于那些接受新辅助治疗和辅助化疗和激素治疗的患者。凋亡抑制蛋白Survivin的存在是预后不良患者生存期缩短的一个非常显著的独立预测因素，值得在其他预后组中作为一个标志物进行研究。
Established clinico–pathological factors can place patients with breast cancer into good and poor prognostic categories, but even within these groups behaviour and response to treatment can differ. This study examined the value of cell cycle and apoptotic regulatory proteins in predicting behaviour in a poor prognostic group. A total of 165 patients, all of whom had died of breast cancer with duration of survival 12–127 months, median 38 months, were examined using immunohistochemistry for proliferation, apoptosis, p53, phosphorylated p53, p21, checkpoint kinase 2 (Chk2), bcl-2, bax, survivin and XIAP. All had received chemotherapy and/or hormonal therapy and were predominantly T2, node positive, grade III with only half oestrogen-receptor (ER) positive. High proliferation, phosphorylated p53, Chk2 and survivin expression correlated with grade III and lack of ER, whereas low proliferation, p21 and bcl-2 related to better grade and presence of ER. On univariate analysis grade, proliferation, phosphorylated p53, bcl-2, ER and survivin related to duration of survival. In multivariate analysis, grade (P=0.001) and survivin (P=0.005) were independent prognostic factors, grade III and presence of survivin relating to shorter survival. The latter was particularly for those patients receiving neoadjuvant therapy and adjuvant chemo- and hormonal therapy. The presence of the inhibitor of apoptosis protein survivin is a highly significant independent predictor of shorter duration of survival of patients with poor prognostic features, and merits investigation as a marker in other prognostic groups.
登录
查看更多内容
影响因子：
5.3
作者：
Dulic, V;Stein, GH;Reed, SI
通讯作者：
Reed, SI
影响因子：
82.9
作者：
BERGH, J;NORBERG, T;HOLMBERG, L
通讯作者：
HOLMBERG, L
影响因子：
11.2
作者：
Asanuma, H;Torigoe, T;Sato, N
通讯作者：
Sato, N
影响因子：
45.3
作者：
Harvey, JM;Clark, GM;Allred, DC
通讯作者：
Allred, DC
影响因子：
7.3
作者：
Hall, PA;McCluggage, WG
通讯作者：
McCluggage, WG